by James Lyons-Weiler, PhD, Popular Rationalism, ©2026
(Mar. 23, 2026) — When does “Standard of Care” cross over into “monopoly enforcement of medical therapy given without indication”?
It’s true: infants are nearly always born with low Vitamin K. But the low levels are consistent across all mammals to varying degrees. Some researchers argue this may be physiologically intentional — there’s speculation (not firmly proven) that lower clotting activity at birth may reduce thrombotic risk during the mechanical stress of delivery, or that it plays a role in vascular remodeling post-birth (e.g., closure of the ductus arteriosus)
The fact that breast milk is universally low in Vit K is hard to explain as a pure oversight of evolution — some argue this suggests the low-K state in early infancy serves some purpose we do not yet fully understand yet.
Every baby ever born has arrived with Vitamin K levels that, by adult standards, look vanishingly low. This is not a modern problem, not a dietary failure, and not a quirk affecting vulnerable infants — it is a universal feature of human birth, consistent across all populations, all diets, and all of recorded medical history. The gut that will eventually produce Vitamin K is sterile at birth. The placenta that could transfer it largely doesn’t. Even breast milk, shaped by millions of years of evolution, contains almost none. Medicine’s response to this has been to treat it as a deficiency — something to be corrected with a shot at birth. But there is a question that rarely gets asked: what if it isn’t a deficiency at all?
Vitamin K does far more in the body than help blood clot. It activates a class of proteins found throughout the brain — including one called Gas6, which guides how neurons survive, how myelin forms, and how the brain prunes its own connections during development. The newborn brain is the most biologically active structure in the known universe during those first weeks of life, and Vitamin K-dependent signals are woven into that process. The low-K state that every newborn arrives with may not be an evolutionary oversight — it may be a carefully tuned biological condition, one that sets the stage for normal neural development in ways we are only beginning to understand. The problem is that we began intervening at scale decades before we thought to ask that question.
Medicine has decided that low Vitamin K at birth is a pathos. They cite a physiological reality rooted in limited placental transfer, sterile newborn gut conditions, naturally low vitamin K content in breast milk, immature liver function, and minimal hepatic storage. This condition, while biologically normal, significantly raises the risk of Vitamin K Deficiency Bleeding (VKDB), a serious condition that can lead to severe bleeding and death in infants. Understanding this complexity is critical to assessing neonatal vitamin K prophylaxis accurately and responsibly.
The vitamin K shot works effectively as prophylaxis against VKDB. However, recognizing the effectiveness of the shot does not justify a one-route policy regime that views every deviation from this standard as inherently problematic, rather than as an opportunity to develop safer and scientifically validated second-line strategies.
Vitamin K deficiency bleeding (VKDB) is real, severe, and preventable. Babies who do not receive vitamin K are said to be approximately 81 times more likely to develop severe bleeding. Late VKDB can occur weeks after birth, with half of late cases involving intracranial bleeding and one in five affected infants dying (CDC, 2022).
Intramuscular (IM) vitamin K is considered the only prophylactic method. The American Academy of Pediatrics (AAP) endorses IM administration as the optimal prophylaxis, noting its reliability and effectiveness during the critical newborn period (Hand, 2022).
While the vitamin K shot works, that alone does not justify a one-route regime that treats every deviation as failure instead of designing a safer second line.
However, a good default is not the same as a good monopoly. Policy and practice monopolization occurs when one method dominates regulations, clinician guidelines, and institutional practices, effectively erasing structured alternatives. In the United States, there is no FDA-approved oral vitamin K formulation for newborns, despite documented clinician use following parental refusal, which leads to inconsistent and unregulated dosing strategies (Loyal, 2019).
Internationally, structured oral alternatives exist and are formally recognized. Canada recommends 2 mg orally at the first feeding, followed by doses at 2–4 weeks and 6–8 weeks if the IM injection is declined, explicitly acknowledging the greater risk associated with oral prophylaxis (CPS, 2022). Similarly, guidelines in Scotland, England, Australia, and throughout Europe describe well-defined multi-dose oral protocols for healthy term infants, clearly stating the need for careful adherence and specifying conditions under which oral prophylaxis is inappropriate (Mihatsch, 2016).
Read the rest here.